

### AMENDMENTS TO THE CLAIMS

Please amend the Claims as follows. Insertions are shown underlined while deletions are ~~struck through~~.

1. (Currently amended) A composition for treating type I allergy selected from human atopic dermatitis and human pollinosis, comprising kaempferol-3-glucoside (astragalin) in unit dosage form, each unit dose comprising from about 0.24 mg to about 210 mg. in an amount effective to treat type I allergy selected from atopic dermatitis and pollinosis.

2. (Canceled)

3. (Canceled)

4. (Canceled)

5. (Canceled)

6. (Canceled)

7. (Canceled)

8. (Canceled)

9. (Canceled)

10. (Canceled)

11. (Currently amended) The method of claim ~~10~~ 24 wherein kaempferol-3-glucoside is administered in an ~~the effective amount of~~ is from about 0.05 0.48 mg per day per adult to about 1.5 mg per day per kg of body weight.

12. (Previously presented) The method of claim 24 wherein the administration is selected from the group consisting of orally, intravenously, topically, intramuscularly, intracutaneously, subcutaneously, intraperitoneally, and by aerosolization.

13. (Previously presented) The method of claim 12, wherein the administration is orally, admixed with a food product.

14. (Previously presented) The method of claim 13, wherein the food product is selected from the group consisting of: juice, soft drinks, teas, powdered soups, jelly, cookies, biscuits, cereal, crackers, candy, breads, noodles, fish paste, chewing gum, ice cream, and chocolate.

15. (Previously presented) The method of claim 24 wherein the administration is between one and 4 doses per day.

16. (Canceled)

17. (Currently amended) The composition of claim 1 wherein ~~the effective~~ the composition is administered such that kaempferol-3-glucoside (astragalin) is administered in an amount is ~~0.05~~ of about 0.48 mg per day per adult to about 1.5 mg per day per kg of body weight.

18. (Previously presented) A pharmaceutical composition comprising the composition of claim 1 with a pharmaceutically acceptable carrier, diluent, or excipient.

19. (Previously presented) The pharmaceutical composition of claim 18, wherein said carrier, diluent, or excipient is selected from the group consisting of powders, lotions, ointments, binders, surfactants, moisturizers, fillers, extenders, wetting agents and food products.

20. (Previously presented) The pharmaceutical composition of claim 18 further comprising: antiseptics, colerants, preservatives, antioxidants, aromatics, and food products.

21. (Previously presented) The composition of claim 1 wherein said kaempferol-3-glucoside is extracted from plants or chemically synthesized.

22. (Previously presented) The composition of claim 21, wherein said plants are selected from the group consisting of: persimmon, amachazuru, gymnema, guava, kuko, striped bamboo, jasmine, sugina, dokudami, loquat, sen-cha, and tien-cha.

23. (Canceled)

24. (Currently amended ) A method for treating human pollinosis in a subject, comprising: administering kaempferol-3-glucoside in an amount of about 0.48 mg per day per adult to about 3 mg per day per kg of body weight to a subject who suffers from pollinosis ~~an effective amount of kaempferol-3-glucoside (astragalin) to treat pollinosis.~~

25. (New) The method of claim 24, wherein sneezing, nasal discharge and/or nasal congestion due to pollinosis are treated.

26. (New) The composition of claim 1, wherein said composition comprises persimmon leaf extract that contains kaempferol-3-glucoside.

27. (New) The method of claim 24, wherein said method comprises administering persimmon leaf extract that contains kaempferol-3-glucoside.